BACKGROUND Proglucagon can be processed to glucagon-like peptide1 (GLP-1) within
the islet, but its contribution to islet function in humans remains unknown. We sought to …

Aims/hypothesis People with isolated impaired fasting glucose (IFG) have normal beta cell
function. We hypothesised that an increased glucose threshold for beta cell secretion …

Background and aims Hyperglucagonemia is a characteristic feature of type 2 diabetes
mellitus (T2DM). We examined the effect of chronic (48–72 h) physiologic increase (+ 50 …

Hyperglucagonemia is a common observation in both obesity and type 2 diabetes, and the
etiology is primarily thought to be hypersecretion of glucagon. We investigated whether …

Objective: To date, the lack of a model of glucagon kinetics precluded the possibility of
estimating and studying glucagon secretion in vivo, eg, using deconvolution, as done for …

Background The liver has a unique role in blood glucose regulation in postprandial,
postabsorptive, and fasting states. In the context of diabetes technology, current maximal …

Background Accompanying islet α-and β-cell dysregulation in type 2 diabetes (T2D) at the
microscopic scale, alterations in body composition at the macroscopic scale may affect the …

Type 2 diabetes is a disease characterized by impaired insulin secretion and defective
glucagon suppression in the postprandial period. We examined the effect of impaired …

It is not completely clear which organs are responsible for glucagon elimination in humans,
and disturbances in the elimination of glucagon could contribute to the hyperglucagonemia …

Glucagon is best known for its contribution to glucose regulation through activation of the
glucagon receptor (GCGR), primarily located in the liver. However, glucagon's impact on …